我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

孕期母血清miRNA-19b诊断胎儿先天性心脏病的初步评价

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第5期
页码:
609-612
栏目:
临床研究
出版日期:
2015-05-05

文章信息/Info

Title:
Clinical value of prenatal maternal serum miRNA-19b in diagnosis of fetal congenital heart disease
作者:
沙 莉; 朱莎莎; 余章斌; 韩树萍
(南京医科大学附属南京妇幼保健院儿科，江苏 南京 210004)
Author(s):
SHA Li;  ZHU Sha-sha;  YU Zhang-bin;  HAN Shu-ping
(Department of Pediatrics, Nanjing Maternal and Child Health Hospital, Nanjing Medical University, Nanjing 210004, Jiangsu, China)
关键词:
心脏病; 先天性; miRNA-19b; 诊断标志物
Keywords:
congenital heart disease;  miRNA-19b;  diagnostic marker
分类号:
R541.1
DOI:
-
文献标识码:
A
摘要:
目的 探讨孕期母血清miRNA在胎儿先天性心脏病(CHD)诊断中的临床价值。方法 选取2009年7月~12月27例我院孕中期CHD胎儿孕妇为研究对象，同时收集27例与病例组在孕妇年龄、胎儿孕周基本匹配的胎儿无畸形的孕妇作为对照组，采用Real-time PCR检测miRNA-19b的表达水平，采用ROC曲线下面积（area under the curve，AUC），对miRNA-19b诊断CHD胎儿的准确性进行初步评价。结果通过检测孕期母血清miRNA-19b的表达水平，结果 表明胎儿CHD病例组孕妇血清miRNA-19b水平显著高于对照组（P<0.01），对miRNA-19b预测胎儿CHD的准确性进行分析，结果表明AUC分别为0.79。结论 孕期母血清miRNA-19b可以预测胎儿CHD的发生风险，作为胎儿CHD的诊断标志物。
Abstract:
AIM To investigate the clinical value of prenatal maternal serum miRNA-19b in the diagnosis of fetal congenital heart disease (CHD). METHODS Twenty-seven pregnant women with fetal CHD in our hospital between July 2011 and June 2012 were included in the study group and 27 pregnant women without fetal CHD were selected as control group. We performed real-time PCR assays to identify and validate the expression of maternal serum miRNAs in fetal CHD. Area under the curve (AUC) was used to evaluate the diagnostic accuracy of the maternal serum miRNA-19b for fetal CHD. RESULTS miRNA-19b was significantly upregulated in pregnant women with fetal CHD, which was validated by real-time PCR. AUC for diagnostic accuracy of miRNA-19b was 0.79. CONCLUSION Maternal serum miRNAs (miRNA-19b) could act as novel and non-invasive biomarkers for prenatal detection of fetal CHD.

参考文献/References

[1]Jelliffe-Pawlowski LL,Walton-Haynes L,Currier RJ.Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results[J].Am J Med Genet A,2008,146A(19):2455-2467.
[2]Yu Z,Han S,Hu P,et al.Potential role of maternal serum microRNAs as a biomarker for fetal congenital heart defects[J].Med Hypotheses,2011,76(3):424-426.
[3]Qin DN,Qian L,Hu DL,et al.Effects of miR-19b overexpression on proliferation, differentiation, apoptosis and Wnt/beta-catenin signaling pathway in P19 cell model of cardiac differentiation in vitro[J].Cell Biochem Biophys,2013,66(3):709-722.
[4]Poon LL,Leung TN,Lau TK,et al.Presence of fetal RNA in maternal plasma[J].Clin Chem,2000,46(11):1832-1834.
[5]Lo YM,Chiu RW.Prenatal diagnosis:progress through plasma nucleic acids[J]. Nat Rev Genet,2007,8(1):71-77.
[6]Wong BC,Chiu RW,Tsui NB,et al.Circulating placental RNA in maternal plasma is associated with a preponderance of 5′mRNA fragments: implications for noninvasive prenatal diagnosis and monitoring[J].Clin Chem,2005,51(10):1786-1795.
[7]Arcelli D,Farina A,Cappuzzello C,et al.Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy:implications for early molecular screening[J].Prenat Diagn,2010,30(3):229-234.
[8]Li H,Guo L,Wu Q,et al.A comprehensive survey of maternal plasma miRNAs expression profiles using high-throughput sequencing[J].Clin Chim Acta,2012,413(5-6):568-576.
[9]Pan M,Ge Q,Li H,et al.Sequencing the miRNAs in maternal plasma from women before and after parturition[J].J Nanosci Nanotechnol,2012,12(5):4035-4043.
[10]Thum T,Catalucci D,Bauersachs J.MicroRNAs:novel regulators in cardiac development and disease[J].Cardiovasc Res,2008,79(4):562-570.
[11]Ai J,Zhang R,Li Y,et al.Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction[J].Biochem Biophys Res Commun,2010,391(1):73-77.
[12]Goren Y,Kushnir M,Zafrir B,et al.Serum levels of microRNAs in patients with heart failure[J].Eur J Heart Fail,2012,14(2):147-154.
[13]Li H,Guo L,Wu Q,et al.A comprehensive survey of maternal plasma miRNAs expression profiles using high-throughput sequencing[J].Clin Chim Acta,2012,413(5-6):568-576.
[14]Gunel T,Zeybek YG,Akcakaya P,et al.Serum microRNA expression in pregnancies with preeclampsia[J].Genet Mol Res,2011,10(4):4034-4040.
[15]Gu H,Li H,Zhang L,et al.Diagnostic role of microRNA expression profile in the serum of pregnant women with fetuses with neural tube defects[J].J Neurochem,2012,122(3):641-649.
[16]Li M,Hu X,Zhu J,et al.Overexpression of miR-19b Impairs Cardiac Development in Zebrafish by Targeting ctnnb1[J].Cell Physiol Biochem,2014,33(6):1988-2002.
[17]Miura K,Morisaki S,Abe S,et al.Circulating levels of maternal plasma cell-free pregnancy-associated placenta-specific microRNAs are associated with placental weight[J]. Placenta,2014,35(10):848-851.
[18]徐爱群,边旭明.胎儿游离RNA在产前诊断中的研究进展[J].国际妇产科学杂志, 2010,37(2):84-89.

备注/Memo

备注/Memo:
收稿日期：2014-06-23.
基金项目：国家自然科学基金项目资助（81070500），南京市医学科技发展资金项目资助（QRX11107）
通讯作者：韩树萍，主任医师，主要从事围产期心脏发育研究 Email：shupinghan@njmu.edu.cn
作者简介：沙莉，副主任医师，硕士 Email：lilisha5000@sina.com
更新日期/Last Update: 2015-04-28